Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Myllanyaon May 01, 2019 4:41pm

32 Views

Post# 29697128

RE:RE:RE:RE:RE:RE:RE:RE:Going to 0.03 or going to 0.15

s3binator is right. All the capitalism system is base on that. The bids are the demand and the ask is the offer. If the demand is stronger then the price must go up, if the offer is bigger then the price must go down. If you don't catch it Pennypatrol you must stop trading stock, it is the base of our economic system. Really simple.

Bullboard Posts

Debt-free cannabis company set for next stage of growth